Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up

American Journal of Surgery

Volumn 194, Issue 4, 2007, Pages 504-506

  Hieken, Tina J ^a,b,d   Cheregi, John ^b   Farolan, Miguel ^c   Kim, Joan ^d   Velasco, Josè M ^a,b,d  

^a RUSH NORTH SHORE MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Edward Hospital   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

Author keywords

Angiogenic factors; Biologic markers; Ductal carcinoma in situ of the breast; Long term follow up; p53; Recurrence

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8 ANTIBODY; ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CARCINOMA IN SITU; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MICROVASCULATURE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548421424     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2007.07.002     Document Type: Article

References (10)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Sanders M.E., Schuyler P.A., Dupont W.D., and Page D.L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103 (2005) 2481-2484
3. Burstein H.J., Polyak K., Wong J.S., et al. Ductal carcinoma in situ of the breast. N Engl J Med 350 (2004) 1430-1441
4. Tang P., Hajdu S.I., and Lyman G.H. Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol 19 (2007) 63-67
5. Fisher E.R., Costantino J., Fisher B., et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Cancer 75 (1995) 1310-1319
6. Hieken T.J., Farolan M.F., D'Alessandro S., and Velasco J. Predicting the biologic behavior of DCIS: an analysis of molecular markers. Surgery 130 (2001) 593-601
7. Cornfield D.B., Palazzo J.P., Schwartz G.F., et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a larger cohort of patients treated with surgery alone. Cancer 100 (2004) 2317-2327
8. Ringberg A., Anagnostaki L., Anderson H., et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37 (2001) 1514-1522
9. de Roos M., de Bock G.H., de Vries J., et al. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 140 (2007) 109-114
10. Tsikitis V.L., and Chung M.A. Biology of ductal carcinoma in situ classification based on biologic potential. Am J Clin Oncol 29 (2006) 305-310